SOX4 has been shown to be upregulated in various cancers, including colorectal, breast, and prostate cancer, where it promotes tumorigenesis and progression by activating critical signaling pathways such as transforming growth factor-beta (TGF-β) and Wnt/β-catenin [22–24]. Here, SOX4 is linked to prostate carcinoma.